While our results demonstrate a disrupted pro-tumorigenic profile of CD44-/- microglia in response to glioma cells, it appears that in vivo, these alterations are not sufficient to significantly affect glioma invasion or increase survival. This evidence concerns the gene CD44 and glioma.